Life Sciences Weekly
Resources
Browse and filter sharp, essential coverage across every life sciences topic that matters.
Life Sciences Weekly
Browse and filter sharp, essential coverage across every life sciences topic that matters.
Vaxcyte's VAX-31 matched both leading adult pneumococcal vaccines in Phase 3, but most at-risk adults still get no pneumococcal shot.
Suzetrigine patients were more likely to skip opioid refills after knee replacement, but only half could get it through insurance.
Lilly's Onswik cuts basal insulin from 365 injections a year to 52. With hypoglycemia results mixed across trials and nursing homes slow to adjust doses, the harder work shifts to the care teams managing the week between injections.
Acadia's remlifanserin missed its Phase 2 primary endpoint with a p-value of 0.0603 but matched placebo on safety. In nursing homes, where CMS now counts 16.98% of long-stay residents on antipsychotics, a safer option could matter as much as efficacy.
AbbVie's Juvmo is the first selective D1/D5 agonist for Parkinson's disease, but in Medicare data 53% of patients had depression, only 2% saw a mental health professional and just 9% reached a movement disorders specialist.
CMS finalized its GLOBE model on September 30, tying Part B drug rebates to prices in 19 other countries. With private pricing deals already signed and net prices undisclosed, the savings are harder to verify.
Ultragenyx's Fayuvi, approved September 18 for Sanfilippo syndrome type A, lists at $3.95 million against an estimated $8 million lifetime cost of care. The harder questions are who pays upfront and who staffs the treatment centers that deliver the dose.
The FDA's new Expedited IND Pilot will pair sponsors with research institutions to shorten first-in-human timelines that can run up to two years, but site turnover of 35% to 61% a year could absorb the time it saves.
Medicare's $50-a-month GLP-1 Bridge reached 600,000 seniors in two months, but its prior authorization asks only for lifestyle counseling, leaving the muscle and bone older patients lose alongside the weight unmanaged.
An FDA panel backed GRAIL's Galleri test 7-2 on benefit and risk, but a split effectiveness vote, a failed NHS primary endpoint and scarce radiologists and endoscopists put the pressure on what happens after a positive result.
Compass and Definium are closing in on FDA filings, but with about 4 million Americans living with treatment-resistant depression and roughly 100,000 on Spravato, the constraint is shifting from the molecule to the clinic chair.
FDA's new hip bone density endpoint lets sponsors run smaller, shorter Phase III trials, but real-world data shows half of hip fracture patients are still untreated a year after surgery.
New research ties sustained GLP-1 use to thousands of avoided knee replacements and shows one-year persistence nearly doubling, yet employer coverage for obesity fell from 72% to 60% in a single year.
Coordinator retention is climbing back toward pre-pandemic levels, yet life sciences remains the world's most talent-scarce industry and patient dropout still runs as high as 30%, exposing a workforce problem sponsors haven't solved.
Three years on, we assess which companies have genuinely rebuilt resilience versus which have made only cosmetic changes, and what a durable supply chain model actually requires.
Quantitative analysis of 900 Phase III programmes reveals that avoidable trial design flaws account for nearly 40% of late-stage failures, creating a systemic drag on industry R&D productivity.
Stubborn pockets of payer resistance are persisting even as biosimilar penetration increases. What the data reveals about the structural shifts driving this divergence, and how long it can last.
Regulators are increasingly accepting real-world evidence to support approval and label expansion decisions. Sponsors who understand the new evidentiary standards will have a significant competitive advantage.
Life sciences teams are losing top scientists to better-paying roles in tech and consulting at an accelerating rate. Leaders who have solved the retention problem share what actually works.
A sweeping meta-analysis of two decades of clinical data asks whether the precision medicine premium has permanently compressed, and what that means for portfolio construction in 2026.
After two years of suppressed deal flow, the biotech acquisition pipeline is opening up. Dealmakers and corporate development teams share what the next 18 months are likely to look like, and which therapeutic areas will lead.
Digital-native health platforms have captured $28 billion in life sciences revenue in three years. We look at which legacy pharma institutions are mounting a credible competitive response, and which are losing ground.
As AI reshapes every function of the enterprise, chief scientific officers face a defining moment: transform the R&D model or risk being outpaced by faster-moving competitors.
New research maps the capabilities separating the CSOs who are driving strategic transformation from those still managing pipelines, and the specific behaviours that define the difference.
A wave of blockbuster biologics is losing patent protection over the next three years. New data on biosimilar penetration rates reveals which therapeutic categories face the steepest revenue erosion.
Life sciences leaders need a framework for navigating the FDA's evolving approval posture. Regulatory strategists break down three scenarios and the pipeline planning implications of each.
The FDA's updated requirements are now in effect. Regulatory and legal teams walk through the six areas most likely to require new data infrastructure, revised submissions, and external audit support.
The technology that powered COVID-19 vaccines is now being applied to oncology, rare disease, and infectious disease programmes at an unprecedented pace.
AI-powered trial design and patient recruitment tools are delivering measurable results. We analysed 80 trials and found that programmes using adaptive AI protocols completed Phase II a median of 14 months faster.
The cell and gene therapy pipeline has never been larger, with over 1,000 active programmes globally. Yet the gap between clinical promise and commercial execution is widening.
The ripple effects of GLP-1 demand are forcing life sciences supply teams to rebuild cost models from the ground up. Here is the analytical framework leading CSOs are using to stress-test their manufacturing assumptions.
The IRA's Medicare drug price negotiation framework is now live. A frank assessment of where most companies stand, which gaps are most urgent to close, and what payers are likely to scrutinise first.
Try a different search term or topic filter.